Replimune Group (NASDAQ:REPL) Sees Strong Trading Volume – What’s Next?

Shares of Replimune Group, Inc. (NASDAQ:REPL) saw strong trading volume on Tuesday . Approximately 10,354,575 shares changed hands during trading, an increase of 128% from the previous session’s volume of 4,542,994 shares.The stock last traded at $6.0720 and had previously closed at $8.63.

Trending Headlines about Replimune Group

Here are the key news stories impacting Replimune Group this week:

• Neutral Sentiment: Trading in REPL was temporarily halted for “news pending,” indicating that a potentially market-moving announcement was expected or being processed. No specific company announcement was provided in the available reports.
• Negative Sentiment: FDA briefing documents released ahead of an advisory committee meeting questioned whether Replimune had provided sufficient evidence that RP1 is effective in advanced melanoma. The concerns have increased expectations of another regulatory setback and drove a sharp decline in the shares. Replimune shares fall after FDA reviewers raise doubts over RP1 melanoma drug efficacy
• Negative Sentiment: Reports said FDA staff raised doubts about RP1’s efficacy ahead of the upcoming advisory committee meeting, leaving investors focused on the risk that the drug could face another rejection or a more difficult regulatory path. Replimune Shares Fall on Negative FDA Comments Ahead of AdCom Meeting
• Negative Sentiment: Several law firms, including Kirby McInerney, Glancy Prongay Wolke & Rotter, Howard G. Smith, and Frank R. Cruz, announced investigations into possible securities-law violations related to Replimune’s disclosures. These announcements do not establish wrongdoing, but they add reputational, litigation, and potential financial risks for shareholders. Kirby McInerney Replimune investigation

Analysts Set New Price Targets

A number of research analysts recently commented on the company. HC Wainwright restated a “sell” rating on shares of Replimune Group in a research report on Monday, April 13th. BMO Capital Markets raised shares of Replimune Group from an “underperform” rating to an “outperform” rating and set a $16.00 price objective for the company in a research report on Tuesday, June 30th. Wedbush increased their price objective on shares of Replimune Group from $6.00 to $9.00 and gave the stock a “neutral” rating in a research note on Tuesday, June 30th. Weiss Ratings raised shares of Replimune Group from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, July 20th. Finally, Jefferies Financial Group restated a “hold” rating and issued a $2.00 target price (down from $13.00) on shares of Replimune Group in a research report on Monday, April 13th. Two equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $8.86.

Replimune Group Stock Performance

The company has a debt-to-equity ratio of 0.63, a current ratio of 4.79 and a quick ratio of 4.79. The stock has a market cap of $461.67 million, a P/E ratio of -1.63 and a beta of 0.86. The stock has a 50-day simple moving average of $9.35 and a 200-day simple moving average of $7.37.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings results on Monday, June 29th. The company reported ($0.76) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.10). Research analysts forecast that Replimune Group, Inc. will post -2.44 earnings per share for the current year.

Insider Activity

In other news, insider Christopher Sarchi sold 12,000 shares of the stock in a transaction on Monday, June 1st. The stock was sold at an average price of $9.24, for a total value of $110,880.00. Following the completion of the transaction, the insider directly owned 180,962 shares in the company, valued at approximately $1,672,088.88. This represents a 6.22% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 5.20% of the company’s stock.

Hedge Funds Weigh In On Replimune Group

Large investors have recently bought and sold shares of the company. ProShare Advisors LLC grew its holdings in shares of Replimune Group by 10.3% during the fourth quarter. ProShare Advisors LLC now owns 16,116 shares of the company’s stock worth $157,000 after purchasing an additional 1,505 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in Replimune Group by 4.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 38,016 shares of the company’s stock worth $159,000 after acquiring an additional 1,712 shares during the last quarter. Ballentine Partners LLC increased its position in Replimune Group by 7.8% in the 4th quarter. Ballentine Partners LLC now owns 23,665 shares of the company’s stock valued at $230,000 after acquiring an additional 1,721 shares during the period. BNP Paribas Financial Markets raised its stake in shares of Replimune Group by 37.5% during the second quarter. BNP Paribas Financial Markets now owns 6,889 shares of the company’s stock valued at $64,000 after acquiring an additional 1,879 shares during the last quarter. Finally, Walleye Capital LLC lifted its holdings in shares of Replimune Group by 3.2% during the first quarter. Walleye Capital LLC now owns 71,592 shares of the company’s stock worth $548,000 after purchasing an additional 2,192 shares during the period. 92.53% of the stock is currently owned by institutional investors.

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.